Qilu Pharmaceutical's Etanercept Biosimilar Application Rejected by NMPA After Three-Year Review
Jun 22, 2022 16:26
CST Updated
16:26
Qilu Pharmaceutical
Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer
On June 21, 2022, Qilu Pharmaceutical received a notification regarding the marketing application of its Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Type II-Antibody Fusion Protein) biosimilar, indicating that it had not been approved.
Qilu Pharmaceutical's Etanercept Biosimilar Marketing Application Was Accepted by the NMPA in May 2019 but Failed to Gain Approval After a Three-Year Review.
*Disclaimer: This article was written by an author who has settled in Sina Medicine News. The views expressed represent the author's personal opinions and do not reflect the position of Sina Medicine News.